DDInter1936 DDInter1658
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Vinblastine {u} (Compound) resembles {v} (Compound) Vindesine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinblastine {u} (Compound) treats {v} (Disease) kidney cancer
Vinblastine {u} (Compound) binds {v} (Gene) TUBB3
Vinblastine {u} (Compound) upregulates {v} (Gene) OSBPL2
Vinblastine {u} (Compound) is included by {v} (Pharmacologic Class) Vinca Alkaloids
Vinblastine {u} (Compound) downregulates {v} (Gene) TMEM168
Vinblastine {u} (Compound) causes {v} (Side Effect) Paraesthesia
Vinblastine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Vinblastine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluorouracil
Vinblastine (Compound) resembles Vindesine (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Vinblastine (Compound) treats kidney cancer (Disease)
Vinblastine (Compound) binds TUBB3 (Gene)
Vinblastine (Compound) upregulates OSBPL2 (Gene)
Vinblastine (Compound) is included by Vinca Alkaloids (Pharmacologic Class)
Vinblastine (Compound) downregulates TMEM168 (Gene)
Vinblastine (Compound) causes Paraesthesia (Side Effect)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Fluorouracil